

Bio-Rad and QIAGEN announce patent settlement and cross-licensing agreement

Hercules, Calif., and Venlo, the Netherlands, July 26, 2023 – Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the companies have agreed to settle their patent dispute pending in the U.S. District Court of Delaware pursuant to a global settlement and patent cross-licensing agreement relating to digital PCR technology.

The settlement provides for a cross-licensing agreement between Bio-Rad and QIAGEN granting each company mutual rights to their respective digital PCR technologies.

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with over 8,000 employees and \$2.8 billion in revenues in 2022. Our customers include universities, research institutions, hospitals, food safety and environmental quality laboratories, and biopharmaceutical companies. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit [bio-rad.com](https://www.bio-rad.com).

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). In 2022, QIAGEN had net sales of more than \$2.1 billion and over 6,200 employees. Further information can be found at <http://www.qiagen.com>.

BIO-RAD is a trademark of Bio-Rad Laboratories, Inc. in certain jurisdictions.

QIAGEN is a trademark of QIAGEN N.V. in certain jurisdictions.

Contacts Bio-Rad:

Investor Relations

Edward Chung
e-mail: ir@bio-rad.com

510-741-6104

Public Relations

Anna Gralinska
e-mail: cc@bio-rad.com

510-741-6643

Contacts QIAGEN:

Investor Relations

John Gilardi
e-mail: ir@QIAGEN.com

+49 2103 29 11711

Public Relations

Thomas Theuringer
e-mail: pr@QIAGEN.com

+49 2103 29 11826